Furosemide clearance in very preterm neonates early in life: A pilot study using scavenged samples

Pediatr Int. 2022 Jan;64(1):e14735. doi: 10.1111/ped.14735. Epub 2021 Dec 17.

Abstract

Background: Furosemide is an off-label drug, frequently used as a diuretic in neonates with oliguria and/or edema. Its clearance in preterm neonates is lower than in term neonates or children. We aimed, herein, to clarify furosemide clearance (CL) in very preterm (VP) neonates (<28 weeks' gestation) within the first 2 weeks of life and identify the factors predictive of the pharmacokinetics (PK) parameters, such as CL.

Methods: Furosemide was administered at 0.5 or 1 mg/kg in a 0.5-h infusion via a syringe pump; blood samples were drawn from an artery or vein after the intravenous injection. The serum furosemide concentration was measured using high-performance liquid chromatography. The PK parameters were then analyzed using Bayesian estimation.

Results: Thirteen blood samples were obtained from 10 VP neonates after intravenous injection. The mean postconceptional age and mean postnatal days at exposure to furosemide were 26.9 weeks and 7.1 days, respectively. The estimated mean CL was 16.5 mL/kg/h. The mean distribution volume (Vd) and elimination half-life (t1/2) were 0.37 L/kg and 15.3 h, respectively. Furosemide CL was negatively associated with serum creatinine (SCr) [CL = 84.2 - 67.1 × SCr (mg/dL)].

Conclusions: Very preterm neonates within the first 2 weeks of life had a higher CL than subjects in other preterm neonatal studies. The SCr level was the sole parameter influencing furosemide CL and might serve as a good index for furosemide dosing in VP neonates.

Keywords: Bayes theorem; creatinine; infant; neonatal intensive care units; pharmacokinetics.

MeSH terms

  • Bayes Theorem
  • Child
  • Furosemide*
  • Humans
  • Infant, Extremely Premature
  • Infant, Newborn
  • Off-Label Use*
  • Pilot Projects

Substances

  • Furosemide